Ultragenyx Pharmaceutical Inc. Stock News

Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.

Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Company Participants Joshua Higa - Director, IR & Corporate Communications Emil Kakkis - Presiden

Ultragenyx (RARE) delivered earnings and revenue surprises of -24.43% and 5.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx (RARE) delivered earnings and revenue surprises of -24.43% and 5.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For AstraZeneca-Daiichi's Enhertu Expands To Earlier Use In Metastatic Breast Cancer The�

NOVATO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ra

NOVATO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for se

NOVATO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for ser

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NOVATO, Calif., April 25, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for s

Physician researcher and biopharmaceutical executive to join R&D Committee Physician researcher and biopharmaceutical executive to join R&D Committee

Ultragenyx (RARE) doses the first patient in a pivotal phase II/III study evaluating setrusumab (UX143) for the treatment of osteogenesis imperfecta.

Ultragenyx (RARE) doses the first patient in a pivotal phase II/III study evaluating setrusumab (UX143) for the treatment of osteogenesis imperfecta.

Global study will evaluate UX143 in pediatric and young adult patients ages 5 to <26 years of age Global study will evaluate UX143 in pediatric and young adult patients ages 5 to <26 years of age